Pain they can’t escape. Movements they can’t control. Frustration others can’t comprehend. For the more than 100 million Americans diagnosed with a neurological condition, this is everyday reality.1
Medication advancements for migraine and epilepsy have given new hope to patients who suffer from often-debilitating neurological conditions. But they’ve also given plan sponsors new challenges: costs are high, prescribers are often unfamiliar with these new treatments and therapy discontinuation is much too common. So we’re leveraging clinical care and cost management tools to help ensure the right patient is on the right therapy, drive better health and deliver savings others don’t, won’t or can’t.
Effective Jan. 1, 2021, our new Neurological Care Value program will move beyond expectations and beyond what’s on the market today, providing the following:
Each year, a migraine sufferer incurs $9K more in costs than a non-sufferer2, and spend for one epilepsy patient is ~$20K3
For more information on how Neurological Care Value works, download the Executive Brief.
SafeGuardRx combines multiple effective cost-containment strategies into a single platform, and enrolled plans experience lower overall trend than nonenrolled plans.1
Clients enrolled in SafeGuardRx see better patient medication adherence, higher therapy completion rates and greater compliance with clinical guidelines.1
specialty and chronic
saved in 2019
SafeGuardRx Savings Calculator
At the heart of SafeGuardRx is our unwavering belief that within the most complex and expensive health care issues exists the greatest opportunity for improvement. We are working with participating plans to harness that opportunity through this platform. As Champions For Better, we take on the risk of managing clinical and financial challenges – and hold the entire health care marketplace accountable – in a way that others don’t, won’t or can’t.
To learn more about how SafeGuardRx can help you deliver better care and better value contact your Express Scripts account team or email us now.